Episodes

Friday, July 10, 2026 In today's episode, Dr. Will Flanary / Dr. Glaucomflecken (@drglaucomflecken) & Eva Johnson cover the retraction of the Advocate trial after FDA reviewers found the avacopan (Tavneos) dataset was unblinded, re-adjudicated, and altered before being relocked, throwing its approval for ANCA-associated vasculitis into doubt. They break down Medicare's new GLP-1 Bridge program, which offers eligible Part D beneficiaries drugs like Wegovy and Zepbound at $50 a month through the e...

Friday, July 3, 2026 In today's inaugural episode, Dr. Will Flanary / Dr. Glaucomflecken (@drglaucomflecken) & Dr. Alok Patel (@alokpatelmd) cover a sharp drop in ACA marketplace enrollment after enhanced tax credits expired, from 24.2 million enrollees in 2025 to roughly 19.2 million in 2026 (a loss of 5 million Americans' health coverage). India is rationing two cornerstone chemotherapy drugs, cisplatin and carboplatin, after supply disruptions tied to rising platinum costs and capped essentia...

Struggling to stay on top of healthcare news because, well, you're too busy working in it? If only there were a way to catch up on things in less time than it takes to get prior auth approved. (Spoiler: There is.) Kick off your Fridays with Dr. Will Flanary (aka Dr. Glaucomflecken), Dr. Alok Patel, Adam Rose, and Eva Johnson as they bring you the week’s most important headlines across clinical care, health policy, publications, medical pop culture, and more. Presented with clear, unbiased, fact-...